Component

PBCA nanoparticle-bound thymulin formulation

5 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. The measured p53 pathway did not respond to thymulin formulations in the reported mouse EAE experiment.

    PBCA nanoparticle-bound thymulin formulation → Mouse measured p53-pathway response Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
    experimental_contrast
    {"intervention": "Thymulin formulation treatment", "comparator": "Disease control", "endpoint": "The measured p53 pathway did not respond to thymulin formulations in the reported mouse EAE experiment.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Mouse EAE; not evidence that all p53 functions are unaffected.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
    plain_language
    The measured p53 pathway did not respond to thymulin formulations in the reported mouse EAE experiment.
    primary_references
    Protective Effect of PBCA Nanoparticles Loaded with Thymulin Against the Relapsing-Remitting Form of Experimental Autoimmune Encephalomyelitis in Mice | 2019 | DOI 10.3390/ijms20215374 | PMID 31671728 | https://doi.org/10.3390/ijms20215374
    source_locator
    Reviewed reference lines 72-72; exact primary location described in quoted passage where extracted.

    Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 72–72

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse EAE; not evidence that all p53 functions are unaffected. · Recorded from source · Recorded from source

    | Relapsing-remitting experimental autoimmune encephalomyelitis in mice | PBCA-bound thymulin altered inflammatory signaling, including p65 Ser276 and JNK responses, with some effects persisting longer than free peptide. | Phosphorylation site and sampling day mattered; later p65 Ser536 differences included a nonsignificant trend. The measured p53 pathway did not respond. This is not demonstrated human multiple-sclerosis treatment. [2019 experiment](https://doi.org/10.3390/ijms20215374) |
    Complete structured claim and evidence

  2. In mouse relapsing-remitting EAE, PBCA-thymulin altered p65 Ser276/JNK responses; later p65 Ser536 differences included a nonsignificant trend.

    PBCA nanoparticle-bound thymulin formulation → Mouse NF-kappa-B signaling readouts Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
    experimental_contrast
    {"intervention": "PBCA-thymulin", "comparator": "Disease controls and free-peptide comparison", "endpoint": "In mouse relapsing-remitting EAE, PBCA-thymulin altered p65 Ser276/JNK responses; later p65 Ser536 differences included a nonsignificant trend.", "effect_direction": "mixed", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Mouse EAE; formulation, phosphorylation site and day-dependent endpoints.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
    plain_language
    In mouse relapsing-remitting EAE, PBCA-thymulin altered p65 Ser276/JNK responses; later p65 Ser536 differences included a nonsignificant trend.
    primary_references
    Protective Effect of PBCA Nanoparticles Loaded with Thymulin Against the Relapsing-Remitting Form of Experimental Autoimmune Encephalomyelitis in Mice | 2019 | DOI 10.3390/ijms20215374 | PMID 31671728 | https://doi.org/10.3390/ijms20215374
    source_locator
    Reviewed reference lines 72-72; exact primary location described in quoted passage where extracted.

    Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 72–72

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse EAE; formulation, phosphorylation site and day-dependent endpoints. · Recorded from source · Recorded from source

    | Relapsing-remitting experimental autoimmune encephalomyelitis in mice | PBCA-bound thymulin altered inflammatory signaling, including p65 Ser276 and JNK responses, with some effects persisting longer than free peptide. | Phosphorylation site and sampling day mattered; later p65 Ser536 differences included a nonsignificant trend. The measured p53 pathway did not respond. This is not demonstrated human multiple-sclerosis treatment. [2019 experiment](https://doi.org/10.3390/ijms20215374) |
    Complete structured claim and evidence

  3. In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic jnk phosphorylation/signaling readouts.

    PBCA nanoparticle-bound thymulin formulation → Mouse JNK assay pool, isoform unresolved Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
    experimental_condition
    Repeated-LPS control tested formulation · PBCA nanoparticle-bound thymulin formulation Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_contrast
    {"intervention": "pbca-thymulin with repeated LPS", "comparator": "Repeated-LPS control", "endpoint": "In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic jnk phosphorylation/signaling readouts.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "pbca-thymulin", "state": "tested formulation"}, {"entity_slug": null, "state": "repeated LPS"}]} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
    plain_language
    In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic jnk phosphorylation/signaling readouts.
    primary_references
    Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation | 2018 | DOI 10.1371/journal.pone.0197601 | PMID 29795607 | https://doi.org/10.1371/journal.pone.0197601
    source_locator
    Reviewed reference lines 71-71; exact primary location described in quoted passage where extracted.

    Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 71–71

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate. · Recorded from source · Recorded from source

    | Mice receiving repeated LPS, free thymulin or PBCA-bound thymulin | Reduced splenic phosphorylation of IKK, p65, JNK, p38 and PKCθ was reported, with changes in stress proteins and apoptosis-related readouts. | Repeated endotoxin exposure is not the same as human infectious sepsis. Free peptide and nanoparticle formulations require separate exposure records. [2018 experiment](https://doi.org/10.1371/journal.pone.0197601) |
    Complete structured claim and evidence

  4. In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic nfkb phosphorylation/signaling readouts.

    PBCA nanoparticle-bound thymulin formulation → Mouse NF-kappa-B signaling readouts Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
    experimental_condition
    Repeated-LPS control tested formulation · PBCA nanoparticle-bound thymulin formulation Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_contrast
    {"intervention": "pbca-thymulin with repeated LPS", "comparator": "Repeated-LPS control", "endpoint": "In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic nfkb phosphorylation/signaling readouts.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "pbca-thymulin", "state": "tested formulation"}, {"entity_slug": null, "state": "repeated LPS"}]} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
    plain_language
    In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic nfkb phosphorylation/signaling readouts.
    primary_references
    Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation | 2018 | DOI 10.1371/journal.pone.0197601 | PMID 29795607 | https://doi.org/10.1371/journal.pone.0197601
    source_locator
    Reviewed reference lines 71-71; exact primary location described in quoted passage where extracted.

    Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 71–71

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate. · Recorded from source · Recorded from source

    | Mice receiving repeated LPS, free thymulin or PBCA-bound thymulin | Reduced splenic phosphorylation of IKK, p65, JNK, p38 and PKCθ was reported, with changes in stress proteins and apoptosis-related readouts. | Repeated endotoxin exposure is not the same as human infectious sepsis. Free peptide and nanoparticle formulations require separate exposure records. [2018 experiment](https://doi.org/10.1371/journal.pone.0197601) |
    Complete structured claim and evidence

  5. In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic p38 phosphorylation/signaling readouts.

    PBCA nanoparticle-bound thymulin formulation → Mouse p38 phosphorylation, isoform unresolved Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
    experimental_condition
    Repeated-LPS control tested formulation · PBCA nanoparticle-bound thymulin formulation Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_contrast
    {"intervention": "pbca-thymulin with repeated LPS", "comparator": "Repeated-LPS control", "endpoint": "In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic p38 phosphorylation/signaling readouts.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "pbca-thymulin", "state": "tested formulation"}, {"entity_slug": null, "state": "repeated LPS"}]} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
    plain_language
    In repeated-LPS mice, PBCA-bound thymulin reduced reported splenic p38 phosphorylation/signaling readouts.
    primary_references
    Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation | 2018 | DOI 10.1371/journal.pone.0197601 | PMID 29795607 | https://doi.org/10.1371/journal.pone.0197601
    source_locator
    Reviewed reference lines 71-71; exact primary location described in quoted passage where extracted.

    Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 71–71

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Repeated-LPS mouse model; not human infectious sepsis. Free and nanoparticle formulations are separate. · Recorded from source · Recorded from source

    | Mice receiving repeated LPS, free thymulin or PBCA-bound thymulin | Reduced splenic phosphorylation of IKK, p65, JNK, p38 and PKCθ was reported, with changes in stress proteins and apoptosis-related readouts. | Repeated endotoxin exposure is not the same as human infectious sepsis. Free peptide and nanoparticle formulations require separate exposure records. [2018 experiment](https://doi.org/10.1371/journal.pone.0197601) |
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.